Supplementary Table 5. Sensitivity analysis on the effect modification by TBIL in participants with normal liver function

Outcome	Group	N	n (%)	Adj. OR/cOR (95% CI)*	*P*	*P* for interaction
Presence of CSVD (Wardlaw)†	Participants with TBIL ≤17 μmol/L					
	No hypertension	1,201	242 (20.2)	Ref.		0.068
	Hypertension	866	353 (40.8)	1.71 (1.28–2.29)	<0.001	
	Participants with TBIL >17 μmol/L					
	No hypertension	424	115 (27.1)	Ref.		
	Hypertension	321	134 (41.7)	1.02 (0.64–1.64)	0.927	
Presence of CSVD (Rothwell)†	Participants with TBIL ≤17 μmol/L					
	No hypertension	1,201	366 (30.5)	Ref.		0.022
	Hypertension	866	470 (54.3)	1.74 (1.33–2.27)	<0.001	
	Participants with TBIL >17 μmol/L					
	No hypertension	424	154 (36.3)	Ref.		
	Hypertension	321	163 (50.8)	1.05 (0.67–1.63)	0.846	
Total CSVD burden (Wardlaw)‡	Participants with TBIL ≤17 μmol/L					
	No hypertension	1,201		Ref.		0.186
	Hypertension	866		1.73 (1.30–2.29)	<0.001	
	Participants with TBIL >17 μmol/L					
	No hypertension	424		Ref.		
	Hypertension	321		1.21 (0.77–1.90)	0.421	
Modified total CSVD burden (Rothwell)‡	Participants with TBIL ≤17 μmol/L					
	No hypertension	1,201		Ref.		0.057
	Hypertension	866		1.75 (1.36–2.26)	<0.001	
	Participants with TBIL >17 μmol/L					
	No hypertension	424		Ref.		
	Hypertension	321		1.13 (0.74–1.72)	0.582	

Participants with abnormal liver function were excluded. Abnormal liver function was defined as elevated alanine aminotransferase (>47 U/L) or elevated aspartate aminotransferase (>37 U/L) or reduced albumin (<3.7 g/dL). All models were adjusted for age, sex, body mass index, current smoking, current drinking, diabetes, dyslipidemia, antihypertensive medication, antiplatelet medication, and anticoagulant medication.

TBIL, total bilirubin; Adj., adjust; OR, odds ratio; cOR, common odds ratio; CI, confidence interval; CSVD, cerebral small vessel disease; Ref., reference.

*The association of hypertension with the presence of CSVD was evaluated using OR, while with CSVD burden was evaluated using cOR. The product term of the hypertension state and TBIL group was included in the model to assess the effect modification by TBIL; †Presence of CSVD was defined as total CSVD or modified total CSVD burden scores ≥1; ‡Total and modified total CSVD burdens were classified as grade 0 (total or modified total CSVD burden score 0), grade 1 (total or modified total CSVD burden score 1), grade 2 (total or modified total CSVD burden score 2–3), or grade 3 (total or modified total CSVD burden score ≥4).